Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 11/20 | 0.47 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | CPT1A | P50416 | 1/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3347973 | 0.96 | PRCP (0.52) | PRCPOPRM1OPRD1HCRTR1HCRTR2 | |
| SCHEMBL1746051 | 0.93 | PRCP (0.47) | PRCPAADAT | |
| SCHEMBL13748216 | 0.90 | PRCP (0.57) | PRCPOPRM1OPRD1HCRTR1HCRTR2 | |
| SCHEMBL1747512 | 0.90 | PRCP (0.49) | PRCPOPRM1OPRD1 | |
| SCHEMBL1746052 | 0.85 | PRCP (0.42) | PRCPAADATOPRM1OPRD1CPT1A | |
| SCHEMBL12174997 | 0.85 | PRCP (0.53) | PRCPOPRM1OPRD1HCRTR1HCRTR2 | |
| SCHEMBL12175268 | 0.83 | PRCP (0.54) | PRCPOPRM1OPRD1 | |
| SCHEMBL12159755 | 0.82 | AADAT (0.43) | AADAT | |
| SCHEMBL1747514 | 0.82 | PRCP (0.45) | PRCPOPRM1OPRD1HCRTR1HCRTR2 | |
| SCHEMBL3350753 | 0.81 | PRCP (0.55) | PRCPHCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9758487-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-12 | — | — | US | claimed |
| US-20160311778-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2016-10-27 | — | — | US | claimed |
| EP-2049522-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-05-14 | — | — | EP | claimed |
| US-20080050336-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-28 | — | — | US | claimed |
| US-20170320833-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-11-09 | — | — | US | disclosed |
| US-9758487-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-12 | — | — | US | disclosed |
| US-20160311778-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2016-10-27 | — | — | US | disclosed |
| US-9421192-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-08-23 | — | — | US | disclosed |
| US-20160067223-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-03-10 | — | — | US | disclosed |
| US-9227961-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-01-05 | — | — | US | disclosed |
| US-20150011754-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-01-08 | — | — | US | disclosed |
| US-8900566-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-02 | — | — | US | disclosed |
| US-20140017195-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-01-16 | — | — | US | disclosed |
| US-8574563-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-11-05 | — | — | US | disclosed |
| US-20130004457-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2013-01-03 | — | — | US | disclosed |
| US-8329159-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-11 | — | — | US | disclosed |
| US-8303944-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-06 | — | — | US | disclosed |
| US-20100158862-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-06-24 | — | — | US | disclosed |
| US-20090068140-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-03-12 | — | — | US | disclosed |
| US-20080050336-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160067223-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | PRCP 190/4885AADAT 2969/4885OPRM1 2169/4885 |
| US-20080050336-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | PRCP 190/4885AADAT 2969/4885OPRM1 2169/4885 |
| US-20090068140-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, PYGL, HCCS | PRCP 190/4885AADAT 2969/4885OPRM1 2169/4885 |
| US-20170320833-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, PYGL, HCCS | PRCP 190/4885AADAT 2969/4885OPRM1 2169/4885 |
| US-20130004457-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | PRCP 190/4885AADAT 2969/4885OPRM1 2169/4885 |
| US-20150011754-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | PRCP 190/4885AADAT 2969/4885OPRM1 2169/4885 |
| US-20160311778-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | PRCP 190/4885AADAT 2969/4885OPRM1 2169/4885 |
| US-20140017195-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | PRCP 190/4885AADAT 2969/4885OPRM1 2169/4885 |
| US-20100158862-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | PRCP 190/4885AADAT 2969/4885OPRM1 2169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.